 |
Gasthalter & Co. represents Rubric Capital Management as it sends a Nov. 10 letter to the board of Chimerix Inc., expressing a lack of confidence in the strategic direction of the biopharmaceutical company.
RCM, which owns an 8.5 percent stake in Chimerix, says the company’s shares trade at a substantial discount to its liquidation value.
It calls for the board “to begin a winddown process and conserve cash to maximize liquidation value available to shareholders, while simultaneously exploring strategic alternatives for ONC201,” treatment for glioma patients.
RCM considers further investment in ONC201, which is likely to need an expensive phase 3 trial, “is not an appropriate course of action for a company of this size and with such an onerous cost of capital.”
Chimerix, which uses Joele Frank, Wilkinson Brimmer Katcher, does not believe liquidation is in the best interests of shareholders as it would deprive them of the significant upside potential of ONC201 and other assets.
"It would also be irresponsible to patients with this deadly disease as it would halt critical progress on ONC201 simply as a means to appease a shareholder making such demands," said Chimerix.
Gasthalter & Co. has Jonathan Gasthalter and Sam Fisher handling RCM.
Joele Frank's Chimerix team includes Nick Lamplough, Dan Moore and Tanner Kaufman.
Interpublic posted a 5.1 percent drop in Q3 net revenues to $2.5B as CEO Philippe Krakowsky reports the final financial results of the publicly traded company.
Joele Frank handles Pine Gate Renewables as the Asheville, NC-based solar power development company declares Chapter 11 in the aftermath of Donald Trump’s cuts to wind & solar tax credits.
Stagwell CEO Mark Penn reports Q3 net revenues jumped 6 percent to $614.5M, a record performance for a non-political period. Operating income soared 45.7 percent to $60.9M.
Joele Frank works for Klöckner Pentaplast as the German maker of plastic films declares Chapter 11. A successful reorganization would slash its its corporate debt by $1.5B.
Teneo represents Metsera, the New York City biotech focused on weight-control products, which is subject to a bidding war between heavyweights Novo Nordisk and Pfizer.
